These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20970373)

  • 1. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.
    Choi JY; Kwon OK; Choi SY; Park YK; Kim SS
    J Clin Virol; 2011 Jan; 50(1):19-25. PubMed ID: 20970373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
    Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
    Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks.
    Kjaer J; Høj L; Fox Z; Lundgren JD
    HIV Med; 2008 Oct; 9(8):642-52. PubMed ID: 18631257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic resistance of resistant strains of HIV type-1 subtype B in China.
    Li J; Lu JF; Dong HH; Bao ZY; Liu SY; Li HP; Zhuang DM; Liu YJ; Li H; Wang Z; Wu H; Li JY
    Chin Med J (Engl); 2006 Dec; 119(23):1972-7. PubMed ID: 17199941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
    Yang J; Geng W; Zhang M; Han X; Shang H
    J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.
    Van Houtte M; Picchio G; Van Der Borght K; Pattery T; Lecocq P; Bacheler LT
    J Med Virol; 2009 Oct; 81(10):1702-9. PubMed ID: 19697398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
    Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
    J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.